Parkinson s Disease - A Junior Doctor s Survival Guide

Similar documents
What is PD? Dr Catherine Dotchin MD MRCP Consultant Geriatrician

Dementia & Movement Disorders

PARKINSON S DISEASE AND PARKINSONISM. Dr Phil Wood Geriatrician, Waitemata DHB Clinical Unit Leader, Waikato DHB

CENTRAL NERVOUS SYSTEM MANAGEMENT OF PARKINSON S DISEASE

Management of Parkinson s Disease in Primary Care

Parkinson s Disease and Dementia. Dr N Samaniego Consultant Physician and Geriatrician

GLOSSARY OF TERMS. This glossary explains the terms and words often used in association with Parkinson s.

Doncaster & Bassetlaw Medicines Formulary

Lewy body dementia Referral for a Diagnosis

Parkinson's s disease - a

The majority of parkinsonism (approx. 80%) is due to idiopathic PD other causes include drug therapy (Table 1),toxins and trauma.

An Introduction to Lewy Body Dementia

Emergency Room Treatment of Psychosis

How To Treat Aphasic Depression

Acute management of Parkinson s

Personal Health Record

Motor Fluctuations in Parkinson s

Chapter 28. Drug Treatment of Parkinson s Disease

PARKINSON S DISEASE IN LONG-TERM-CARE SETTINGS

PARKINSON S DISEASE INTRODUCTION. Parkinson s disease is defined as a disease of the nervous system that affects voluntary movement.

Multiple System Atrophy guide (

SLEEP AND PARKINSON S DISEASE

Clinical Psychopharmacology

Parkinson s Disease Symptoms Guide

Disordered sleep at night has long been

Parkinson s Disease: Factsheet

Diagnosis and Treatment of Parkinson s Disease: A Systematic Review of the Literature

drug treatments for parkinson s

Anti-Parkinsonism Drugs

PARKINSONISM. akinetic-rigid syndrome

NEW PATIENT CLINICAL INFORMATION FORM. Booth Gardner Parkinson s Care & Movement Disorders Center Evergreen Neuroscience Institute

Current evidence suggests that Parkinson s tends to develop

Unmet Needs for Parkinson s Disease Therapeutics

Parkinson s Disease (PD)

Donepezil hydrochloride (Aricept) Drug treatment for Alzheimer s disease

Ronald Postuma, Christos Galatas. A Guide to the Non-Motor Symptoms. Parkinson s Disease. A patient-friendly booklet for:

Dementia with Lewy bodies

Levels of evidence and grades of recommendation

NEUROIMAGING in Parkinsonian Syndromes

PARKINSON'S DISEASE The Disorder and Current Therapy Copyright 2008, Daniel Kassicieh, D.O.

Sleep Difficulties. Insomnia. By Thomas Freedom, MD and Johan Samanta, MD

These guidelines are intended to support General Practitioners in the care of their patients with dementia both in the community and in care homes.

COMPASS Therapeutic Notes on Management of Parkinson s Disease

III./ Parkinsonian syndrome (parkinsonism, atypical parkinsonian disorders) in neurodegenerative diseases

SLEEP DIFFICULTIES AND PARKINSON S DISEASE Julie H. Carter, R.N., M.S., A.N.P.

Parkinson's disease. Definition. Symptoms

drug treatments for parkinson s

SUMMARY OF RECOMMENDATIONS

How To Treat An Elderly Patient

Prevalence of Parkinsonism and its aetiological subtypes within patients with movement disorders

Chad Christine, MD UCSF

Depression is a common biological brain disorder and occurs in 7-12% of all individuals over

Memantine (Ebixa) Drug treatment for Alzheimer s disease

Welcome to the Medical Risk Webinar: a taster of Assessing and Managing Medical Risk for Insurers courses. 26 April 2013

Recognition and Treatment of Depression in Parkinson s Disease

Journal Club. Parkinsonismo iatrogeno

PARTNERS IN PARKINSON S. Parkinson s Disease Guide

ABC s of Parkinson s Disease 4/29/15 Karen Parenti, MS, PsyD

UNIFIED PARKINSON'S DISEASE RATING SCALE

HOW TO HELP HURTING PEOPLE (YOURSELF AND OTHERS)

Pharmacological Management of Parkinson s Disease Robert Iansek

Chapter 18 Drugs Used for Psychoses Learning Objectives Identify signs and symptoms of psychotic behavior Describe major indications for the use of

Parkinson s disease (PD) is a progressive neurodegenerative

cme: The Current Treatment of Parkinson's Disease

CLINICAL GUIDELINE FOR THE MANAGEMENT OF INPATIENTS WITH PARKINSONS DISEASE

**Form 1: - Consultant Copy** Telephone Number: Fax Number: Author: Dr Bernard Udeze Pharmacist: Claire Ault Date of issue July 2011

Antipsychotic drug prescription for patients with dementia in long-term care. A practice guideline for physicians and caregivers

Public Assessment Report. Dopamine agonists: pathological gambling and increased libido TABLE OF CONTENTS

Meeting Report: XX WFN World Congress on Parkinson s Disease and Related Disorders

What You and Your Family Should Know

Disorders Considered. A Brief Synopsis of Select Neurological Disorders. Neurological and Psychiatric Symptoms. Neurological Basis

Parkinson s Disease Medications

MOTION AND E-MOTION. Andrea Cavanna MD PhD FRCP

Medication Management of Lewy Body and Parkinson's Dementias

CLINICAL PRACTICE GUIDELINES FOR PHYSICAL THERAPY IN PATIENTS WITH PARKINSON'S DISEASE

Transcription:

Parkinson s Disease - A Junior Doctor s Survival Guide Professor Richard Walker Consultant Geriatrician Hon. Professor of Ageing & Interna<onal Health Northumbria Healthcare NHS Founda<on Trust #G4J14 @ElderlyMedEd

Geriatricians ideally suited to care for Parkinson s disease Ø Many patients elderly Ø Multiple co-morbidity Ø Multi-system disease Ø Requires multidisciplinary team

North Tyneside Prevalence Ø Population of 110,000. Ø Case finding hospital records, GP records (diagnostic lists and drug treatment), other hospitals (eg Neurology). Ø Age-standardised prevalence = 160/100,000. Comparable with previous studies (Porter et al 2006).

Aetiological theory for PD

What causes Parkinson s? Ageing Genes Environment Parkinson s disease Possible protective effect: smoking and caffeine

When do clinical signs of Parkinson's develop? Striatal dopamine levels Reduced by 80% Cell loss in the substantia nigra Reaches 50%

The Braak hypothesis Stage 5 and 6: Changes spread to the cortex Stage 3 and 4: Pathology spreads to the midbrain and basal ganglia Stage 1 and 2: Pathology confined to certain structures in the brain stem, not yet the substantia nigra Image adapted from The Professionals Guide to Parkinson s Disease

DIAGNOSIS

Differential Diagnoses Ø Drug induced parkinsonism Ø Cerebrovascular parkinsonism Ø Lewy body dementia Ø Alzheimers disease Ø Multi system atrophy Ø Progressive supranuclear palsy Ø Benign essential tremor Ø Other weird and wonderful conditions

Brain Bank Criteria Ø Developed by PD society brain bank study Ø Retrospectively Ø Sensitivity 96% Ø Specificity 82% Ø Tool now used in epidemiological studies in PD

Diagnosis of Parkinsonism - signs Ø BRADYKINESIA and one of: Ø Muscular rigidity Ø 4-6Hz rest tremor Ø Postural instability

Probable most important diagnostic criteria Ø Asymmetrical onset Ø Progressive condition Ø Responsive to levodopa

Speech Hypomimia Reduced arm swing Posture Tremor Arising from a chair Bradykinesia Rigidity Motor symptoms of Parkinson s Motor symptoms of Parkinson's Postural instability Micrographia Turning in bed Turning Freezing Gait festination Shuffling gait Falls

Investigations Ø Routine blood investigations Ø DAT Scan normal in essential tremor and drug-induced Parkinsonism Ø +/- MRI Scan Ø?Dopamine challenge reasonable dose for reasonable length of time Ø Sniffin sticks objective change in sense of smell at diagnosis in over 70%

Partnerships in PD PDS Service Users Carers Age Concern Voluntary Bodies Family Health Visitor Consultant Social Worker Person with PD Friends Physiotherapy PD Nurse OT Dietician Psychiatrist GP District Nurse SALT Psychologist

The most important partnership Person with PD Person who knows about PD

Drug classes in Parkinson s Levodopa MAO-B inhibitors Monoamine oxidase B inhibitors Anticholinergics DAs Dopamine agonists COMTs Catechol-Omethyltransferase inhibitors

L-dopa Benefits Disadvantages Most effective symptomatic therapy Good response for morbidity and probably mortality Benefits may be enhanced by: Ø dopamine agonists Ø CR preparations Ø COMT inhibitors Short and long term side effects Complications with longterm use include motor fluctuations and dyskinesias Do not stop disease progression Free radical formation?

Specifics of L dopa prescribing Ø Sinemet 110, 125, 275 Halfs etc etc Ø Start low go slow Ø What dose do you go to? Ø CR preparations Ø Dispersible madopar

Typical pattern of wearingoff during the day

Dopamine agonists Benefits Disadvantages Proven antiparkinsonian activity, although less than levodopa Motor fluctuations and dyskinesias are encountered less if monotherapy Do not produce free radicals Initiation of treatment requires careful dose titration Limited evidence for add on therapy Non-ergolines (ropinirole/ pramipexole) can cause confusion (particularly in the elderly), nausea, dizziness, fainting and daytime sleepiness Ergot-derived agonists (cabergoline, bromocriptine and pergolide) can cause additional, lung and peritoneal fibrosis now not used

Impulse Control Disorder A person s inability to resist a temptation or impulse More likely to happen in those with a previous history of novelty seeking or risk taking behaviours Compulsive behaviours have been reported as a side effect with levodopa and dopamine agonists Behaviours can include: l Pathological gambling l Hypersexuality l Compulsive eating l Compulsive shopping l Punding

Ø Thalamotomy l Surgery drug-resistant unilateral tremor Ø Pallidotomy l drug-induced dyskinesias Ø Sub-thalamotomy - experimental Ø Stimulation - bilateral l l l thalamic (tremor) bilateral subthalamic nucleus (parkinsonism, tremor, dystonia) pallidal (dyskinesias)

Non-motor symptoms Neuropsychiatric Autonomic Sleep disturbance Sensory symptoms Dementia Depression Apathy Anxiety Loss of libido REM sleep disorder RLS Vivid dreams Daytime somnolence Dystonia Constipation Urinary incontinence Erectile dysfunction Excessive sweating Postural hypotension Excessive salivation Pain Paraesthesia

Sleep Disorders Ø Two thirds of patients Ø Insomnia l l Initial Sleep maintenance (sleep fragmentation) Parasomnias l l REM sleep behaviour disorder Vivid dreams Ø Excessive daytime sleepiness and sleep attacks Ø Obstructive sleep apnoea and stridor (NB MSA)

NEUROPSYCHIATRIC COMPLICATIONS

Ø Depression Ø Anxiety and agitation Ø Sleep disturbances Ø Vivid dreams Ø Hallucinations Ø Delirium Ø Dementia

Confused patient Ø Delirium screen Ø Decrease PD medication in following order l Anticholinergic, Amantadine, MAOIB, DA, COMT-I, LD Ø Consider atypical neuroleptic, eg Quetiapine (Clozapine) start at low dose of 12.5mgs Ø Cholinesterase inhibitors, eg Donepezil, Rivastigmine (NB patch) may improve cognition and hallucinations

Swallowing problems Ø Look for reversible cause Ø Get PD medication into patient l NG tube l Rotigotine patch l Apomorphine subcutaneously (NB Domperidone) Ø Don t consider for end of life care unless adequate dopaminergic replacement, or on advice from PD specialist team

General tips for inpatients Ø Make sure they get medication on time Ø Know how to contact PD specialist team, eg PD nurse specialist will often know patients well Ø Ask about hallucinations Ø Any illness will often make PD symptoms worse, and it takes PD patients longer to recover

Useful Contacts for PD Ø Parkinson s UK Ø BGS movement disorders section Ø richard.walker@nhct.nhs.uk